Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
SLU-PP-332 represents a paradigm shift in metabolic disease management, offering exercise-like benefits for patients unable to engage in physical activity. Preclinical data robustly support its efficacy in enhancing mitochondrial function and insulin sensitivity.
intended strictly for laboratory research use and is not for human consumption or clinical application.
SLU-PP-332 represents a paradigm shift in metabolic disease management, offering exercise-like benefits for patients unable to engage in physical activity. Preclinical data robustly support its efficacy in enhancing mitochondrial function and insulin sensitivity.
intended strictly for laboratory research use and is not for human consumption or clinical application.